Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals has reported Other Non-Current Liabilities for 6 years, with the latest figure at $42.0 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 85.95% year-over-year to $42.0 million in Q2 2026; TTM through Jun 2026 was $42.0 million, a 85.95% decrease from a year earlier, with the FY2025 full-year figure at $52.0 million, down 85.75% from the prior year.
• Other Non-Current Liabilities was $42.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $41.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $428.0 million in Q4 2022, with the low at $41.0 million in Q1 2026.
• Average Other Non-Current Liabilities over 5 years is $242.6 million, with a median of $299.0 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities gained 1.67% in 2024, then slumped 86.2% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $428.0 million in 2022, then dropped by 16.12% to $359.0 million in 2023, then grew by 1.67% to $365.0 million in 2024, then tumbled by 85.75% to $52.0 million in 2025, then fell by 19.23% to $42.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $42.0 million (Q2 2026), $41.0 million (Q1 2026), and $52.0 million (Q4 2025), per Business Quant data.